Figure 4. Pharmacokinetic studies of CN-105 demonstrate CNS bioavailability.

Concentration of [¹⁴C]- radioactivity in the plasma and central nervous system of male CD-1 mice following an intravenous dose of [¹⁴C]-radiolabeled CN-105 peptide(A). For clarity, the concentration of [¹⁴C]- radioactivity during the first 6 hours only is depicted in(B).